promo_leaderboard Ad
‹ All stocks
PHVS

Pharvaris N.V.

PHVS · NASDAQ · Healthcare
$32.03
▼ $0.42 (-1.28%)
$27.74 $30.11 $32.48 $34.85 $32.02 Oct 19 Nov 02 Nov 17
Day range
$31.29 – $32.42
Year range
$23.01 – $43.25
Open
$32.00
Previous close
$32.44
Market cap
$2.25B
Volume (24h)
$22.6K
Volume (52w)
$725.08K
Performance
7D
▼ -5.78%
1M
▲ 7.57%
3M
▼ -11.70%
6M
▲ 4.86%
1Y
▲ 28.51%
YTD
▲ 20.94%
3Y
▲ 110.69%
5Y
▲ 120.25%
All-time
▲ 10.43%
Key statistics
P/E ratio
-10.25
EPS (TTM)
$-3.13
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
70.2M
About Pharvaris N.V.

Pharvaris N.V. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and bringing to market treatments for uncommon diseases. Its primary pipeline asset, PHA121, is a small molecule bradykinin B2-receptor antagonist currently undergoing Phase II clinical trials for hereditary angioedema (HAE). Additionally, the company is advancing PHVS416, a swift-acting, on-demand soft capsule designed to alleviate acute HAE attacks, which is also in Phase 2 development. A third candidate, PHVS719, an extended-release prophylactic tablet aimed at preventing HAE episodes, is progressing through Phase 1 trials. Established in 2015 and headquartered in Leiden, the Netherlands, Pharvaris operates across the Netherlands, Switzerland, and the United States.

Visit website
Country: United States of America
More in Healthcare